Vol. 23 No. 5 (2025): Blood Transfusion 5-2025 (September-October)
Full Issue
pdf
Editorial
Review
-
When is ABO-incompatible plasma safe to transfuse? Defining an empirical estimation of anti-A/anti-B in ABO incompatible plasma-containing blood products: Transfusion of ABO-incompatible plasma
-
The Red Blood Cell-Improving Transfusions for Chronically Transfused Recipients (RBC-IMPACT) study: protocol description of an international multi-site observational clinical study: RBC-IMPACT protocol description
-
Chimeric antigen receptor therapy for hematological malignancies: a pediatric perspective from leukapheresis to infusion: CAR T cell therapy for pediatric hematologic malignancies
Original article
-
Molecular characterization of variant D antigen expression among 56,445 blood donors in East India: RHD variants in East India
-
Pilot study of ABO-isogroup or universal plasma pools with or without pathogen reduction treatment: Pathogen reduced plasmas from maxi-pools
-
Effectiveness of oral platelet lysate gel to treat oral mucosal manifestations associated with chronic graft versus host disease: PL gel for oral cGvHD: efficacy and safety
Announcements
Winter Closure
The Editorial Office will be closed from December 31 to January 7, 2026.
Season’s greetings to all our readers, authors, and reviewers.
Read moreSIMTI 2026
46° Convegno Nazionale di Studi di Medicina Trasfusionale - Abstract Book (in Italian)
Read moreSETS 2026
35° Congreso de la Sociedad Española de Transfusión Sanguínea y Terapia Celular - SETS - Abstract Book (in Spanish), is online (https://www.bloodtransfusion.it/bt/issue/view/81).Madrid, 4-6 June 2026.
Read moreEditorial Office Closure Notice
Please note that the BT Editorial Office will be closed until August 26, 2026.
During this period, responses to inquiries and the processing of manuscripts may be delayed. All editorial activities will resume as usual after this date.
Thank you for your understanding.
Best regards,
BT Editorial Office
Read more
Impact Factor 2025
We are pleased to announce that Blood Transfusion has achieved a 2025 Impact Factor of 2.7.
Read more